文献速递胃肠动力与功能性疾病

甲哌丙嗪甲磺酸盐(NG101)治疗胃轻瘫安全性及疗效的2期随机双盲安慰剂对照研究

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Metopimazine Mesylate (NG101) in Participants With Gastroparesis.
PubMed 文献 · Am J Gastroenterol · 2025-05-14

这项12周多中心2期试验将161例胃轻瘫患者随机分配至NG101 5、10、20 mg每日4次或安慰剂组,主要终点(第7-12周恶心严重程度较基线变化)各组虽下降但未显著优于安慰剂;恶心患者整体印象变化在第1-12周所有剂量组均显著优于安慰剂,安全性良好,特发性胃轻瘫患者趋势更佳。

要点

  • 主要终点未达统计学显著性:第7-12周恶心严重程度下降未显著优于安慰剂。
  • 恶心患者整体印象变化第1-12周所有NG101剂量组均显著优于安慰剂。
  • 安全性和疗效趋势在特发性胃轻瘫患者中优于糖尿病胃轻瘫患者。

核心结论

  • NG101在主要终点降低恶心严重程度上未达统计学显著性,但安全性良好且部分次要终点显著改善。
  • 需进一步研究以确定NG101是否为特发性胃轻瘫患者的有效治疗。

研究设计与样本

  • 12周2期多中心随机双盲安慰剂对照试验,纳入161例胃轻瘫患者(45.3%糖尿病性,54.7%特发性)。
  • NG101 5、10、20 mg每日4次与安慰剂比较。
  • 主要终点为治疗期第7-12周糖尿病和特发性胃轻瘫症状日记(DIGS-DD)平均恶心严重程度较基线的变化。

主要发现

  • 所有治疗组第7-12周DIGS-DD恶心严重程度评分较基线下降,但与安慰剂相比改善无统计学显著性。
  • 第1-12周所有NG101剂量组恶心患者整体印象变化与安慰剂相比有统计学显著改善。
  • 安全性和疗效趋势在特发性胃轻瘫患者中优于糖尿病胃轻瘫患者。

关键数值与推荐

  • DIGS-DD采用0-10分数字评定量表评估过去24小时内恶心、腹痛、早饱、餐后饱胀和呕吐的最严重程度。
  • 患者整体印象变化问卷(包括恶心)每周评估,采用7点平衡序数量表。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究以确定NG101是否为特发性胃轻瘫患者的有效治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is an urgent need for effective and safe treatment of gastroparesis. Metopimazine, a selective, peripherally restricted dopamine D 2 receptor antagonist, is used in France for the symptomatic treatment of nausea and vomiting and chemotherapy-induced nausea and vomiting. The aim of this study is to assess the safety and efficacy of oral NG101, the mesylate salt of metopimazine, for the treatment of gastroparesis. METHODS: We conducted a 12-week phase 2 multicenter trial with NG101 5, 10, and 20 mg 4 times a day versus placebo. The primary end point was the change in mean nausea severity from the Diabetic and Idiopathic Gastroparesis Symptoms Daily Diary (DIGS-DD) during weeks 7-12 of the Treatment Period from baseline. The DIGS-DD measured nausea, abdominal pain, early satiety, postprandial fullness, and vomiting at their worst in the past 24 hours using a 0-10 point numeric rating scale. Patient Global Impression of Change questionnaires, including nausea, were assessed weekly using a 7-point balanced ordinal score. RESULTS: Of 161 randomized participants (45.3% diabetic and 54.7% idiopathic), mean DIGS-DD nausea severity scores decreased from baseline during weeks 7-12 in all treatment groups, but these improvements were not statistically significant compared with placebo. However, there were statistically significant improvements in nausea Patient Global Impression of Change during weeks 1-12 for all treatment groups compared with placebo. Trends in safety and efficacy favored patients with idiopathic gastroparesis compared with those with diabetic gastroparesis. DISCUSSION: While NG101 did not meet statistical significance in its primary end point for reducing nausea severity, it demonstrated a favorable safety profile and significant improvement in some secondary end points. Further study is needed to determine whether NG101 is an effective treatment for patients with idiopathic gastroparesis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Loesch J, Hamza E, Pasricha PJ, et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Metopimazine Mesylate (NG101) in Participants With Gastroparesis. Am J Gastroenterol. 2025. PMID: 40367443. doi:10.14309/ajg.0000000000003534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。